Performance characteristics of a high throughput automated transcription mediated amplification test for SARS-CoV-2 detection

- 3 Jimmykim Pham^a, Sarah Meyer^a, Catherine Nguyen^a, Analee Williams^a, Melissa Hunsicker^a, Ian
- 4 McHardy^b, Inessa Gendlina^c, D. Yitzchak Goldstein^c, Amy S. Fox^c, Angela Hudson^a, Paul Darby^a, Paul
- 5 Hovey^a, Jose Morales^a, James Mitchell^a, Karen Harrington^a, Mehrdad Majlessi^a, Joshua Moberly^a, Ankur
- 6 Shah^a, Andrew Worlock^a, Marion Walcher^a, Barbara Eaton^a, Damon Getman^{a†}, Craig Clark^a
- 7 ^aHologic Inc. 10210 Genetic Center Dr, San Diego CA 92121
- 8 ^bScripps Health, Microbiology Laboratory, San Diego CA 92121
- 9 ^cMontefiore Medical Center, Department of Pathology, Bronx, NY 10458
- 10 [†]Corresponding Author
- 11

12 ABSTRACT (210 words)

- 13 The COVID-19 pandemic caused by the new SARS-CoV-2 coronavirus has imposed severe challenges on
- 14 laboratories in their effort to achieve sufficient diagnostic testing capability for identifying infected
- 15 individuals. In this study we report the analytical and clinical performance characteristics of a new, high-
- 16 throughput, fully automated nucleic acid amplification test system for the detection of SARS-CoV-2. The
- 17 assay utilizes target capture, transcription mediated amplification, and acridinium ester-labeled probe
- 18 chemistry on the automated Panther System to directly amplify and detect two separate target sequences in
- 19 the ORF1ab region of the SARS-CoV-2 RNA genome. The probit 95% limit of detection of the assay was
- 20 determined to be 0.004 TCID₅₀/ml using inactivated virus, and 25 c/ml using synthetic *in vitro* transcript
- 21 RNA targets. Analytical sensitivity (100% detection) was confirmed to be 83 194 c/ml using three
- 22 commercially available SARS-CoV-2 nucleic acid controls. No cross reactivity or interference was observed
- with testing six related human coronaviruses, as well as 24 other viral, fungal, and bacterial pathogens, at
- high titer. Clinical nasopharyngeal swab specimen testing (N=140) showed 100%, 98.7%, and 99.3%
- 25 positive, negative, and overall agreement, respectively, with a validated reverse transcription PCR NAAT for
- 26 SARS-CoV-2 RNA. These results provide validation evidence for a sensitive and specific method for
- 27 pandemic-scale automated molecular diagnostic testing for SARS-CoV-2.
- 28

- 29 Abstract Word Count: 210
- 30 Body Word Count: 2114
- 31 Number of Tables: 4 (1 Supplemental)
- 32 Number of Figures: 3 (1 Supplemental)
- 33 Number of references: 18
- 34
- 35 Key Words: SARS-CoV-2, automation, high throughput, Aptima, TMA
- 36
- 37 <u>Conflict of Interest Statement</u>
- All authors except I. McHardy, I. Gendlina, D.Y. Goldstein, and A.S. Fox are scientists employed by
- Hologic Inc., the manufacturer of the diagnostic test systems used in this study. IM, IG, DYG and ASFdeclare no conflicts of interests.
- 41 Funding Statement
- 42 This study was funded by Hologic Inc.
- 43
- 44 Running Title: High throughput automated TMA test for SARS-CoV-2
- 45

46 INTRODUCTION

- 47 Coronavirus disease-19 (COVID19) is a novel respiratory illness caused by severe acute respiratory
- 48 syndrome coronavirus 2 (SARS-CoV-2), a novel *Sarbecovirus* that emerged from the region of Wuhan,
- 49 China in late 2019 (1). People with COVID-19 experience mild to severe respiratory symptoms including
- 50 fever, cough and shortness of breath or difficulty breathing (2), although some individuals experience no
- 51 symptoms at all (3).
- 52 The COVID-19 pandemic has occurred across all continents, adding more than 100,000 new SARS-CoV-
- 53 2 cases globally each day (4,5). As communities begin reopening and relaxing quarantine measures, there
- 54 is the potential risk for an upsurge in cases and rates of viral transmission. The availability of validated
- 55 high-throughput diagnostic tests is therefore essential for rapidly and efficiently informing patient
- 56 management decisions, implementing hospital infection prevention practices, and for guiding public
- 57 health responses to wide-scale infection control measures to reduce transmission in populations.

58	To meet the need for pandemic-scale diagnostic testing, we have developed and validated a high-
59	throughput, fully automated nucleic acid amplification test (NAAT) for direct amplification and detection
60	of SARS-CoV-2 RNA from specimens of infected individuals. The assay employs target capture,
61	transcription mediated amplification (TMA) and acridinium ester-labeled probe chemistries to enable a
62	sample-to-result solution for detection of two different conserved target regions within the ORF1ab
63	region of the SARS-CoV-2 genome. Herein, we describe the analytical and clinical performance
64	characteristics of the assay.

65

66 MATERIALS AND METHODS

67 **Transcription Mediated Amplification Test for SARS-CoV-2**. The Aptima® SARS-CoV-2 assay

68 utilizes magnetic bead-based target capture, isothermal TMA of RNA, and dual kinetic acridinium ester-

69 labeled probe hybridization for the isolation, amplification, and detection of an internal process control

70 RNA, and two unique sequences within the ORF1ab region of the SARS-CoV-2 viral genome. The assay

71 is performed on the automated Panther® and Panther Fusion® instruments (both from Hologic Inc, San

72 Diego, USA), and received FDA Emergency Use Authorization (EUA) on May 14, 2020. It is intended

for the qualitative detection of SARS-CoV-2 RNA isolated and purified from nasopharyngeal (NP) swab,

nasal swab (NS), mid-turbinate and oropharyngeal (OP) swab, NP wash/aspirate, or nasal aspirate

specimens, obtained from individuals meeting COVID-19 clinical and/or epidemiological criteria. Sample

reagent loading access, automated RNA extraction,

amplification, detection, and results reporting. Time to first result is 3 h 30 min, with a capacity of

approximately 1,025 results per 24 h per instrument system.

79 Comparison Assay. The validated EUA Panther Fusion SARS-CoV-2 reverse transcription PCR (RT-

80 PCR) assay (Hologic Inc.) was used as a comparator assay for clinical performance studies. This assay

81 was performed as previously described (6).

82

84 Analytical Performance

85 Limit of Detection. The analytical sensitivity of the SARS-CoV-2 TMA assay was assessed using 2 lots of reagents to test 60 replicates each of dilution panels containing cultured SARS-CoV-2 virus strain 86 USA-WA1/2020 (BEI Resources, Manassas, VA) and diluted in Aptima specimen transport medium 87 88 (STM) matrix to a range of 0.03 to 0.0003 tissue culture infectious dose 50 per ml (TCID₅₀/ml). Also 89 tested were replicates (n = 43 to 60) of panels consisting of two *in vitro* transcribed (IVT) RNA targets, 90 corresponding to two unique target sequences within the ORF1ab region of the SARS-CoV-2 RNA 91 genome, diluted in STM. Assay positivity for both studies was determined using a pre-defined cutoff 92 value of 560 kilo relative light units (kRLU). Results were analyzed by probit analysis (normal model) to 93 determine the 95% limit of detection (LOD). Analytical sensitivity was confirmed by testing 20 replicates each of SARS-CoV-2 virus diluted in four specimen matrices (pooled NP swab, STM, saline and Liquid 94 95 Amies transport medium (Copan, Murrieta, CA)) at 0.003 TCID₅₀/ml for NP swab, STM and saline, and 96 0.003 and 0.01 TCID₅₀/ml for Liquid Amies.

97 Analytical Specificity/Interference. Analytical specificity of the SARS-CoV-2 TMA assay was

98 determined by evaluating assay cross-reactivity and interference using 30 non-target microorganisms (17

99 viral species, including 6 non - SARS-CoV-2 coronaviruses, 11 bacterial species, and 2 fungal species;

100 N=3 replicates each) at the highest titer achievable. Thirty NP swab specimens obtained from consented

asymptomatic donors were also tested to represent diverse microbial flora in the human respiratory tract.

102 Interference by high-titer non-target organisms was assessed by testing of 3 replicates of each organism in

- the presence of low titer (0.03 TCID₅₀/ml) SARS-CoV-2 virus. Cross reactivity by high-titer non-target
- 104 organisms was assessed in the absence of SARS-CoV-2 virus.

105 SARS-CoV-2 Commercial Control Panel Testing. Stock SARS-CoV-2 control panel materials from

- 106 three commercial suppliers (Exact Diagnostics (Fort Worth, TX) SARS-CoV-2 Standard, cat no.
- 107 COV019; SeraCare (Milford, MA) AccuPlex SARS-CoV-2 Verification Panel, cat no. 0505-0126; and
- 108 ZeptoMetrix (Buffalo, NY) SARS-CoV-2 External Run Control cat no. NATSARS(COV2)-

109	ERC0831042) were diluted in STM to 6 concentrations ranging from 833 to 8 copies per ml (c/ml) and
110	multiple replicates (n = 20 to 40) were tested with the SARS-CoV-2 TMA assay. The control panels were
111	also tested with the SARS-CoV-2 RT-PCR assay on the automated Panther Fusion platform.
112	Clinical Performance
113	Specimen Collection. Residual de-identified NP swab samples were collected by standard methods from
114	140 symptomatic patients at two different US clinical sites (San Diego, CA and The Bronx, NY).
115	Specimens were transported to the laboratory and tested with the SARS-CoV-2 TMA assay and the
116	Fusion SARS CoV-2 RT-PCR assay. An additional clinical sample set consisting of paired NP swab, OP
117	swab and NS specimens were collected from 38 patients; complete sets (containing all three specimen
118	types) were obtained from 35 patients. NS samples were collected first by inserting the swab into the
119	subject's nostril past the inferior turbinate, approximately 3 cm, twisting the swab in mid-turbinate area
120	for 3 to 5 seconds and placing the swab into a tube of STM. OP swab samples were collected immediately
121	following NS samples by swabbing the posterior pharynx for 3-5 seconds and placing the swab into a
122	specimen tube. Samples were frozen and shipped to Hologic (San Diego, CA) for testing.
123	RESULTS
124	Data for the analytical sensitivity determination of the SARS-CoV-2 TMA assay are shown in Figure 1.
125	Using a pre-determined cutoff value of 560 kRLU, the assay yielded 100% positivity at a concentration of
126	0.01 TCID ₅₀ /ml of SARS-CoV-2 virus and at 100 c/ml of SARS-CoV-2 IVT RNA targets. Using probit
127	analysis, the 95% limit of detection was determined to be 0.004 TCID ₅₀ /ml (95% CI: $0.003 - 0.007$) for
128	SARS-CoV-2 virus, and 25.4 c/ml (95% CI: 16.9 - 50.5) for ORF1ab IVT RNA targets. Analytical
129	sensitivity for the assay was confirmed by testing SARS-CoV-2 virus in 4 specimen matrices (pooled NP
130	swab specimens, STM, saline, and Liquid Amies transport medium) at 0.003 TCID ₅₀ /ml. All specimen
131	matrices yielded 95% positivity (19/20 replicates detected) at this concentration, except Liquid Amies
132	transport medium, which was 85% (17/20) positive at 0.003 TCID ₅₀ /ml and 100% (20/20) positive at 0.01

- $133 \qquad TCID_{50}/ml \ (\textbf{Table 1}).$

134 Analytical specificity of the SARS-CoV-2 TMA assay was determined by evaluating assay cross-

- reactivity and interference using 30 non-target viral, bacterial and fungal microorganisms at the highest
- titer achievable, as well as in 30 NP swab specimens obtained from consented asymptomatic donors at
- 137 low risk of SARS-CoV-2 infection. As shown in the Supplemental Table, none of the microorganisms or
- 138 NP swab specimens tested caused cross-reactivity in the absence of SARS-CoV-2 target or interfered with
- 139 TMA detection in the presence of SARS-CoV-2 spiked at 0.03 TCID₅₀/ml.
- 140 The clinical accuracy of the SARS-CoV-2 TMA assay was compared to the SARS-CoV-2 RT-PCR assay
- 141 using 140 patient NP swab specimens (**Table 2**). This analysis resulted in positive, negative, and overall
- agreements of 100% (95%CI: 94.3% 100%), 98.7% (95%CI: 92.9% 99.8%), and 99.3% (95%CI:
- 143 96.1% 99.3%), respectively. Clinical performance of the SARS-CoV-2 TMA assay was also assessed by
- testing sets of NP swabs, OP swabs, and nasal swabs co-collected from 35 symptomatic patients
- suspected of being infected with SARS-CoV-2. Figure 2 shows the SARS-CoV-2 TMA assay had 100%
- 146 positive and negative agreements of the NP swab specimens with the co-collected OP swab and nasal
- 147 swab specimens. Similar results were obtained for the paired specimen sets using the SARS-CoV-2 RT-
- 148 PCR assay (Supplemental Figure).
- 149 SARS-CoV-2 control panel materials from three commercial suppliers (Exact Diagnostics, SeraCare,
- 150 ZeptoMetrix) were evaluated by building dilution panels of each control material and testing multiple
- 151 replicates with both the SARS-CoV-2 TMA assay and the SARS-CoV-2 RT-PCR assay (**Table 3**). Both
- assays yielded similar results. For the Exact Diagnostics SARS-CoV-2 control, the TMA and RT-PCR
- assays each had 100% detection down to 83 c/ml (N=40 each). For the SeraCare SARS-CoV-2 control,
- the TMA assay was 100% at 83 c/ml (N=20) while the RT-PCR assay was 90% at 83 c/ml and 100% at
- 155 194 c/ml (N=20 for both). The SARS-CoV-2 TMA assay (N=37) and the SARS-CoV-2 RT-PCR assay
- 156 (N=40) were both 100% reactive at 194 c/ml using the ZeptoMetrix control material.

158 **DISCUSSION**

159 The availability of large-scale diagnostic testing for SARS-CoV-2 addresses a current critical need for 160 identifying the prevalence and spread of the virus in populations and for guiding public health policies 161 and interventions to minimize incident infections. This study describes the performance characteristics of 162 a new high-throughput isothermal TMA NAAT that employs a complete sample-to-result automation 163 system to maximize sample testing throughput in clinical laboratories. The analytical performance data demonstrates the assay is highly sensitive and specific for detection of viral SARS-CoV-2 RNA and has 164 165 high clinical agreement (100% positive agreement, 98.7% negative agreement) with a EUA validated RT-PCR assay for SARS-CoV-2 RNA. 166 167 The unprecedented need for SARS-CoV-2 testing has resulted in national shortages in sample collection 168 materials including VTM, prompting the CDC and FDA to recommend optional specimen collection 169 media, such as saline and Liquid Amies (7, 8). To ensure comparable performance across various 170 collection media, we evaluated analytical sensitivity of the SARS-CoV-2 TMA assay in NP swab matrix 171 (NP swabs collected in VTM), STM, saline, and Liquid Amies transport medium using inactivated 172 SARS-CoV-2 virus. NP swab matrix, Aptima STM, and saline demonstrated 95% detection at 0.003 $TCID_{50}/ml$, whereas Liquid Amies showed slightly lower sensitivity at 0.01 $TCID_{50}/ml$. Despite this small 173 174 difference in analytical sensitivity, these results suggest that all media are acceptable for use for clinical 175 sample collection.

176 NP swab specimens have been considered the gold standard sampling method for respiratory virus

177 infection (9) as it has been reported that nasal swab or OP swab samples may have a slightly lower

sensitivity compared to NP swabs (10, 11). However, given the challenges of collection device shortages

179 for SARS-CoV-2 diagnosis, particularly NP swabs and VTM, the use of nasal swab and OP swab as

180 alternate samples for diagnosis of SARS-CoV-2 has been evaluated. The CDC recently removed NP swab

- as the "preferred" sample type from their sample collection guidelines (7) and others have reported
- 182 comparable performance of NS and OP swabs for the diagnosis of SARS-CoV-2 (12-15). Our data shows

183	strong agreement between SARS-CoV-2 detection from NS and OP swabs compared to paired NP swab
184	samples for the SARS-CoV-2 TMA and SARS-CoV-2 RT-PCR assays. We did observe for one patient
185	positive NP and nasal swab results, but negative results in the paired OP swab, however overall the data
186	indicate that both NS and OP swab specimens are adequate sample types for diagnosis of SARS-CoV-2.
187	The performance of other SARS-CoV-2 NAATs that have received Emergency Use Authorization has
188	been characterized using commercially available inactivated virus preparations (e.g., BEI Resources,
189	Manassas, VA) or synthetic RNA quality control materials. Our evaluation of three different external
190	RNA control materials demonstrated comparable analytical sensitivity with both the SARS-CoV-2 TMA
191	assay and the SARS-CoV-2 RT-PCR assay, with LOD values between 83 c/ml – 194 c/ml. These
192	analytical sensitivity values correlate with previously reported LOD values by Zhen et al (16). However,
193	using LOD values as determined by external control material to assess or compare assay performance
194	warrants some caution as different control materials may give considerably different results for the
195	absolute LOD value (16) and the reported RNA or DNA stock concentrations of these materials may
196	differ from true concentrations (17).
197	Limitations of this study include the small number of clinical specimens available for testing, and the
198	absence of discordant result resolution by testing with a third assay. The paired specimen testing (NS and
199	OP) included only 35 patients (14 of which were positive). The specimens that were included did span a
200	typical clinical titer range for the virus (SARS-CoV-2 RT-PCR Ct values ranged from 14.5 to 37.1).
201	Additional clinical data should be collected to more fully assess and compare performance between these
202	sample types.
203	In summary, the SARS-CoV-2 TMA assay is highly sensitive and specific and provides an automated
204	high-throughput testing solution for large-scale diagnostic testing for the virus. The assay system is able
205	to process and generate results for $> 1,000$ samples per day enabling medical centers, reference
206	laboratories and public health laboratories to efficiently process and analyze very high volumes of

207 specimens for the detection of SARS-CoV-2 RNA (18).

208 **REFERENCES**

- 1. WHO. Q&A on coronaviruses (COVID-19). World Health Organization, 2020.
- 210 https://www.who.int/news-room/q-a-detail/q-a-coronaviruses. Accessed May 17, 2020.
- 211 2. CDC. Coronavirus Disease 2019 (COVID-19) Symptoms of Coronavirus. Centers for Disease
- 212 Control and Prevention, 2020. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-
- 213 <u>testing/symptoms.html</u>. Accessed May 17, 2020.
- 3. Nishiura H, Kobayashi T, Miyama T, Suzuki A, Jung S, Hayashi K, Kinoshita R, Yang Y, Yuan
- B, Akhmetzhanov AR, Linton NM. 2020. Estimation of the asymptomatic ratio of novel
- coronavirus infections (COVID-19). Int J Infect Dis 94:154-155.
- 2174. WHO. Coronavirus Disease (COVID-19) Dashboard. World Health Organization, 2020.
- 218<u>https://covid19.who.int/</u>. Accessed June 13, 2020.
- 5. JHU CSSE. Rate of Positive Tests in the US and States Over Time. COVID-19 Data Repository
- by the Center for Systems Science and Engineering at Johns Hopkins University, 2020.
- 221 <u>https://coronavirus.jhu.edu/testing/individual-states</u>. Accessed June 13, 2020.
- 222 6. Zhen W, Manji R, Smith E, Berry GJ. 2020. Comparison of Four Molecular In Vitro Diagnostic
- Assays for the Detection of SARS-CoV-2 in Nasopharyngeal Specimens. J Clin Micro
- 224 <u>https://doi.org/10.1128/JCM.00743-20</u> [Epub ahead of print].
- 225 7. CDC. Interim Guidelines for Collecting, Handling, and Testing Clinical Specimens for COVID-
- 226 19. <u>https://www.cdc.gov/coronavirus/2019-nCoV/lab/guidelines-clinical-specimens.html</u>.
- 227 Accessed June 13, 2020.
- 8. FDA. FAQs on Testing for SARS-CoV-2. <u>https://www.fda.gov/medical-devices/emergency-</u>
 situations-medical-devices/faqs-testing-sars-cov-2#whatif. Accessed Jun 10, 2020
- 9. Ginocchio CC, McAdam AJ. 2011. Current Best Practices for Respiratory Virus Testing. J Clin
 Microbiol 49(9Suppl):S44-S48.
- 10. Lambert SB, Whiley DM, O'Neill NT, Andrews EC, Canavan FM, Bletchly C, Siebert DJ, Sloots
- 233 TP, Nissen MD. 2008. Comparing nose-throat swabs and nasopharyngeal aspirates collected from

234	children with symptoms for respiratory virus identification using real-time polymerase chain
235	reaction. Pediatrics 122: e615–e620.

- 11. Meerhoff TJ, Houben ML, Coenjaerts FE, Kimpen JL, Hofland RW, Schellevis F, Bont LJ. 2010.
- 237 Detection of multiple respiratory pathogens during primary respiratory infection: nasal swab
- 238 versus nasopharyngeal aspirate using real-time polymerase chain reaction. Eur J Clin Microbiol
- **239** Infect Dis 29: 365-371.
- 240 12. Wölfel R, Corman VM, Guggemos W, Seilmaier M, Zange S, Müller MA, Niemeyer D, Jones
- 241 TC, Vollmar P, Rothe C, Hoelscher M, Bleicker T, Brünink S, Schneider J, Ehmann R,
- Zwirglmaier K, Drosten C, Wendtner C. 2020. Virological assessment of hospitalized patients
 with COVID-2019. Nature 581(7809):465-469.
- 244 13. Berenger, B.M, Fonseca, K, Schneider, A, Hu, J, Zelyas, N. 2020. Sensitivity of Nasopharyngeal,
 245 Nasal and Throat Swab for the Detection of SARS-CoV-2. medRxiv
- 246 https://doi.org/10.1101/2020.05.05.20084889. Accessed 01Jun2020.
- 247 14. Péré H, Podglajen I, Wack M, Flamarion E, Mirault T, Goudot G, Hauw-Berlemont C, Le L,
- 248 Caudron E, Carrabin S, Rodary J, Ribeyre T, Bélec L, Veyer D. 2020. Nasal Swab Sampling for
- 249 SARS-CoV-2: a Convenient Alternative in Times of Nasopharyngeal Swab Shortage. J Clin
- 250 Microbiol 58(6):e00721-20.
- 251 15. Wehrhahn MC, Robson J, Brown S, Bursle E, Byrne S, New D, Chong S, Newcombe JP,
- 252 Siversten T, Hadlow N. 2020. Self-collection: An appropriate alternative during the SARS-CoV-2
- pandemic. J Clin Virol 128:104417 https://doi.org/10.1016/j.jcv.2020.104417 [Epub ahead of
 print]
- 255 16. Smith E, Zhen W, Manji R, Schron D, Duong S, Berry GJ. 2020. Analytical and Clinical
- 256 Comparison of Three Nucleic Acid Amplification Tests for SARS-CoV-2 Detection. bioRxiv
- 257 https://doi.org/10.1101/2020.05.14.097311. Accessed 10Jun2020.

258	17. Jue E, Ismagilov RF. 2020. Commercial stocks of SARS-CoV-2 RNA may report low
259	concentration values, leading to artificially increased apparent sensitivity of diagnostic assays.
260	medRxiv https://doi.org/10.1101/2020.04.28.20077602 . Accessed 10Jun2020.
261	18. Craney AR, Velu P, Satlin MJ, Fauntleroy KA, Callan K, Robertson A, LaSpina M, Lei B, Chen
262	A, Alston T, Rozman A, Loda M, Rennert H, Cushing M, Westblade, LF. 2020. Comparison of
263	Two High-Throughput Reverse Transcription-Polymerase Chain Reaction Systems for the
264	Detection of Severe Acute Respiratory Syndrome Coronavirus 2. J Clin Micro
265	https://doi.org/10.1128/JCM.00890-20 [Epub ahead of print]
266	
267	
268	
269	
270	
271	
272	
273	
274	
275	
276	
277	
278	
279	
280	
281	
282	
283	
284	
285	



Figure 1. Analytical sensitivity of automated Aptima SARS-CoV-2 TMA assay for detection of SARS-CoV-2 Open Reading Frame 1ab (orf1ab) RNA. IVT, in vitro RNA transcript; TCID₅₀, Tissue Culture Infectious Dose 50%.



Figure 2. Agreement (A) between 35 sets of co-collected nasopharyngeal swab, oropharyngeal swab, and nasal swab clinical specimens with positive (+) and negative (-) Aptima SARS-CoV-2 TMA assay results. Scatter plot (**B**) of corresponding Aptima SARS-CoV-2 TMA assay positive and negative kRLU signal for each sample type.

Α.



Supplemental Figure. Agreement (**A**) between 35 sets of co-collected nasopharyngeal swab, oropharyngeal swab, and nasal swab clinical specimens with positive (+) and negative (-) Panther Fusion SARS-CoV-2 RT-PCR assay results. Scatter plot (**B**) of RT-PCR Ct values corresponding to Panther Fusion SARS-CoV-2 RT-PCR assay positive samples for each swab type.

Table 1. Confirmation of Aptima SARS-CoV-2 TMA assay limit of detection in different specimen matrices.

Target	Matrix	TCID ₅₀ /ml	n/N (%)	Average kRLU (%CV)
	ND	0	0/0 (0)	278 (2.9)
	INF	0.003	19/20 (95)	908 (17.2)
	STM	0	0/0 (0)	289 (2.2)
SARS-		0.003	19/20 (95)	835 (24.4)
CoV-2	Saline	0	0/0 (0)	288 (2.4)
virus		0.003	19/20 (95)	876 (24.8)
		0	0/0 (0)	286 (1.8)
	Liquid Amies	0.003	17/20 (85)	877 (24.7)
		0.01	20/20 (100)	1100 (3.9)

STM, Aptima specimen transport medium. kRLU, kilo relative light unit.

Table 2. Agreement analysis (%, (95% confidence interval) between the Aptima SARS-CoV-2 TMA assay and the Panther Fusion SARS-CoV-2 RT-PCR assay for nasopharyngeal swab specimens.

Aptima SARS-CoV-2 TMA Result	+	-	Total
+	64	1	65
-	0	75	75
Total	64	76	140

Panther Fusion SARS-CoV-2 RT-PCR Result

Overall Agreement	99.3%	(96.1% - 99.3%)
Positive Agreement	100%	(94.3% - 100%)
Negative Agreement	98.7%	(92.9% - 99.8%)

SARS-CoV-2 Control	Concentration	Aptima	Panther Fusion
Vendor	(c/ml)	SARS-CoV-2	SARS-CoV-2
		TMA	RT-PCR
		n/N (%)	n/N (%)
Exact Diagnostics	833	40/40 (100)	38/38 (100)
SARS-CoV-2 Standard	417	40/40 (100)	39/39 (100)
	194	40/40 (100)	40/40 (100)
	83	40/40 (100)	40/40 (100)
	19	35/39 (90)	30/40 (75)
	8	29/39 (74)	21/40 (53)
SeraCare	833	20/20 (100)	20/20 (100)
Accuplex [™] SARS-CoV-2	417	19/19 (100)	20/20 (100)
Verification Panel	194	19/19 (100)	20/20 (100)
	83	20/20 (100)	18/20 (90)
	19	16/40 (40)	11/40 (28)
	8	7/40 (18)	4/40 (10)
ZeptoMetrics	833	39/39 (100)	40/40 (100)
SARS-CoV-2 (recombinant)	417	40/40 (100)	40/40 (100)
	194	37/37 (100)	40/40 (100)
	83	39/40 (97.5)	32/40 (80)
	19	12/40 (30)	14/40 (35)
	8	12/40 (30)	8/40 (20)

Table 3. Performance of Aptima SARS-CoV-2 TMA and Panther Fusion SARS-CoV-2 RT-PCR assays for detection of commercially available SARS-CoV-2 controls.

Supplemental Table. Microorganism cross reactivity and interference of the Aptima SARS-CoV-2 TMA assay.

		SARS-CoV-2 Unspiked				SARS-CoV Spiked ^a	-2
Microorganism	Concentration	N Tested	N Detected	% Detected	N Tested	N Detected	% Detected
No organism Control	N/A	3	0	0	3	3	100
Human coronavirus 229E	1.00E+05 TCID50/ml	3	0	0	3	3	100
Human coronavirus OC43	1.00E+05 TCID50/ml	3	0	0	3	3	100
Human coronavirus HKU1	1.00E+06 c/ml	3	0	0	3	3	100
Human coronavirus NL63	1.00E+04 TCID50/ml	3	0	0	3	3	100
SARS-coronavirus	1.00E+06 c/ml	3	0	0	3	3	100
MERS-coronavirus	1.00E+04 TCID50/ml	3	0	0	3	3	100
Adenovirus	1.00E+05 TCID50/ml	3	0	0	3	3	100
Human Metapneumovirus (hMPV)	1.00E+06 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 1	1.00E+05 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 2	1.00E+05 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 3	1.00E+05 TCID50/ml	3	0	0	3	3	100
Parainfluenza virus 4	1.00E+03 TCID50/ml	3	0	0	3	3	100
Influenza A (H3N2)	1.00E+05 TCID50/ml	3	0	0	3	3	100

		SARS-CoV-2 Unspiked		SARS-CoV-2 Spiked ^a			
Microorganism	Concentration	N Tested	N Detected	% Detected	N Tested	N Detected	% Detected
Influenza B	2.00E+03 TCID50/ml	3	0	0	3	3	100
Enterovirus (e.g. EV68)	1.00E+05 TCID50/ml	3	0	0	3	3	100
Respiratory syncytial virus	1.00E+05 TCID50/ml	3	0	0	3	3	100
Rhinovirus	1.00E+04 TCID50/ml	3	0	0	3	3	100
Chlamydia pneumonia	1.00E+06 IFU/ml	3	0	0	3	3	100
Haemophilus influenzae	1.00E+06 CFU/ml	3	0	0	3	3	100
Legionella pneumophila	1.00E+06 CFU/ml	3	0	0	3	3	100
Mycobacterium tuberculosis	1.00E+06 TCID50/ml	3	0	0	3	3	100
Streptococcus pneumonia	1.00E+06 CFU/ml	3	0	0	3	3	100
Streptococcus pyogenes	1.00E+06 CFU/ml	3	0	0	3	3	100
Bordetella pertussis	1.00E+06 CFU/ml	3	0	0	3	3	100
Mycoplasma pneumoniae	1.00E+06 CFU/ml	3	0	0	3	3	100
Pneumocystis jirovecii	1.00E+06 nuc/ml	3	0	0	3	3	100
Candida albicans	1.00E+06 CFU/ml	3	0	0	3	3	100
Pseudomonas aeruginosa	1.00E+06 CFU/ml	3	0	0	3	3	100

		SARS-CoV-2 Unspiked			SARS-CoV-2 Spiked ^a		
Microorganism	Concentration	N Tested	N Detected	% Detected	N Tested	N Detected	% Detected
Staphylococcus epidermidis	1.00E+06 CFU/ml	3	0	0	3	3	100
Streptococcus salivarius	1.00E+06 CFU/ml	3	0	0	3	3	100
Negative clinical NP swab specimens (N=30 ^b)	N/A	90	0	0	90	90	100

^aSARS-CoV-2 inactivated cultured virus spiked at 0.03 TCID₅₀/ml (3x LoD)

^bEach NP swab specimen was tested in triplicate for a total of 90 replicates in the absence and presence of spiked SARS-CoV-2 inactivated virus.